麻豆传媒

• share
• favorite_border

鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

• share
• favorite_border

路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

• share
• favorite_border

UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.

• share
• favorite_border

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.

• share
• favorite_border

鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

• share
• favorite_border

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

• share
• favorite_border

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

• share
• favorite_border

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

• share
• favorite_border

New research has shown that hypertensive individuals who maintain optimal control of several key health risk factors鈥攕uch as blood pressure, cholesterol, and lifestyle behaviors鈥攃an significantly reduce their risk of dying prematurely. The study found that with each additional risk factor brought under control, the risk of death from cancer, cardiovascular disease, and other causes dropped substantially. Most importantly, those who achieved high levels of joint risk factor control had no greater risk of early death than people without hypertension. This suggests that a comprehensive, multi-pronged approach to managing hypertension could effectively eliminate the excess mortality risk associated with the condition.